Developer docs
API playgroundTry for free, no card

Search company profiles

Skyhawk Therapeutics

Full company profile

uuid00002pp

Namestring
Skyhawk Therapeutics
Legal namestring
Skyhawk Therapeutics, Inc.
Websiteurl
skyhawktx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Skyhawk Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics that modulate RNA expression to address historically undruggable disease targets. The company's proprietary SKYSTAR platform integrates four complementary components — SKYSTAR (target assessment system combining bioinformatic, structural, and computational biology data), SKYLIBRARY (custom-built compound libraries), SKYSEQ (proprietary multiplex screening), and SKYAI (machine learning toolset) — to discover and advance orally bioavailable small molecules that act on RNA upstream of protein expression. The platform has been used to screen more than 700 RNA targets for pharma partners.

The company's lead asset, SKY-0515, is an oral small molecule RNA splicing modulator for Huntington's disease that targets two pathogenic mechanisms simultaneously — mutant huntingtin (mHTT) protein reduction and PMS1-mediated somatic CAG repeat expansion. SKY-0515 has progressed through Phase 1 trials (demonstrating up to 72% HTT mRNA reduction in healthy volunteers and 69% mHTT reduction at 12 months in patients) and is now enrolling a global Phase 2/3 FALCON-HD pivotal trial across 8 countries. Additional pipeline assets include SKY-1214 (an IND-ready FANCL/FANCI RNA splicing modulator for multiple myeloma and non-Hodgkin's lymphoma) and four preclinical rare neurological disease programs (SKY-0925, SKY-2100, SKY-4100, SKY-4200).

Skyhawk generates revenue through upfront payments, development and regulatory milestones, and tiered royalties from pharma collaborations, with over $550 million in upfront payments received to date from nine major partners including Bristol-Myers Squibb, Biogen, Genentech, Sanofi, Takeda, Vertex, Merck & Co., Merck KGaA (deal exceeding $2 billion), and Ipsen (deal worth up to $1.8 billion). The company has raised over $600 million in equity financing, including a $133 million round in September 2021 led by Fidelity. Headquartered in Waltham, Massachusetts with European operations in Basel, Switzerland, Skyhawk is preparing for direct commercial launch of SKY-0515 in Australia via the TGA provisional approval pathway (application submitted March 2026) and targeting major market approvals by 2027, supported by its appointment of a Chief Commercial Officer in March 2026.

Short descriptiontext

Skyhawk Therapeutics is a clinical-stage biotechnology company developing orally bioavailable small molecule RNA splicing modulators through its proprietary SKYSTAR platform to target historically undruggable proteins in neurodegenerative, oncology, and rare diseases, with lead asset SKY-0515 in Phase 2/3 for Huntington's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA splicing modulators, small molecule therapeutics, neurology drug discovery, targeted oncology therapeutics, rare disease pipeline
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
RNA-targeting small molecule therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharma Collaboration Payments and Milestones
TypeLicensing Royalties
Description

Skyhawk generates revenue through upfront payments, milestone payments, and tiered royalties from pharma partnerships. Upfront payments from pharma collaborations total over $550 million, with additional potential from milestone payments under collaboration agreements including deals with Merck KGaA ($2B+ total deal value) and Ipsen (up to $1.8B total deal value).

skyhawktx.com
2Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Once regulatory approvals are obtained, Skyhawk plans to commercialize its proprietary pipeline products, starting with SKY-0515 for Huntington's disease, through direct commercial teams targeting healthcare providers and patients globally.

skyhawktx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1SKYSTAR
Description

Proprietary RNA-targeting small molecule drug discovery platform integrating bioinformatics, structural biology, and machine learning

skyhawktx.com
+3 more records
Core offering1 text field

Skyhawk Therapeutics discovers and develops oral small molecule drug candidates that modify RNA expression to target historically undruggable proteins implicated in neurodegenerative, oncologic, neuromuscular, rare, and fibrotic diseases. Its clinical-stage pipeline is led by SKY-0515 for Huntington's disease (Phase 2/3 FALCON-HD pivotal trial) and includes SKY-1214 for multiple myeloma and non-Hodgkin's lymphoma (IND-ready), plus four preclinical rare neurology programs. The proprietary SKYSTAR discovery platform integrates SKYSTAR, SKYLIBRARY, SKYSEQ, and SKYAI to generate partnered and wholly-owned assets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 69% reduction in mutant huntingtin protein (mHTT) at 9mg dose at 12 months in Phase 1/2 trial
+5 more records
Product overview1 text field

Skyhawk Therapeutics is a clinical-stage biotechnology company developing a portfolio of small molecule RNA-modulating drug candidates. The core platform is SKYSTAR, which integrates four components (SKYSTAR target assessment, SKYLIBRARY compound libraries, SKYSEQ multiplex screening, and SKYAI machine learning) to discover RNA-targeting small molecules. Lead product SKY-0515 is in Phase 2/3 pivotal trial for Huntington's disease. Additional programs include SKY-1214 (IND-ready for oncology: multiple myeloma and NHL), SKY-0925, SKY-2100, SKY-4100, and SKY-4200 for rare neurological diseases. The company has collaborations with eight major pharmaceutical partners including BMS, Biogen, Genentech, Ipsen, Merck, Sanofi, Takeda, and Vertex. All drug candidates are small molecules taken orally with demonstrated blood-brain barrier penetration.

Product and service7 records
1SKY-0515
CategoryClinical-stage drug candidate (Huntington's disease)
Description

Oral, once-daily small molecule RNA splicing modulator for early-stage Huntington's disease that simultaneously reduces mutant huntingtin (mHTT) protein and PMS1 mRNA. Currently in Phase 2/3 FALCON-HD pivotal trial with TGA provisional approval pathway eligibility in Australia and broader market entry anticipated by 2027.

2SKY-1214
CategoryClinical-stage / IND-ready oncology candidate
Description

First-in-class oral FANCL/FANCI RNA splicing modulator for difficult-to-treat multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) that targets the Fanconi anemia DNA damage repair pathway. IND-ready with completed IND-enabling studies.

3SKY-0925
CategoryPreclinical rare neurology program
Description

Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options. Part of Skyhawk's internal neurology pipeline.

4SKY-2100
CategoryPreclinical rare neurology program
Description

Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options.

5SKY-4100
CategoryPreclinical rare neurology program
Description

Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options.

6SKY-4200
CategoryPreclinical rare neurology program
Description

Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options.

7SKYSTAR Platform
CategoryDrug discovery platform
Description

Proprietary RNA-targeting small molecule drug discovery platform integrating target assessment (SKYSTAR), custom compound libraries (SKYLIBRARY), multiplex screening (SKYSEQ), and machine learning (SKYAI). Used to support partnered collaborations with Bristol-Myers Squibb, Biogen, Genentech, Sanofi, Takeda, Vertex, Merck (MSD), Ipsen, and Merck KGaA.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Merck KGaA, Darmstadt, Germany
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-08-18
Description

Skyhawk entered an option agreement granting Merck KGaA exclusive global rights to drug candidates pursued under the collaboration upon option exercise. Total deal value exceeds $2 billion including upfront and milestone payments, along with royalties on future sales. Skyhawk uses its SKYSTAR platform to identify small molecule candidates directed at specific RNA targets designated by Merck KGaA in neurological indications. Following option exercise, Merck KGaA assumes responsibility for further development and commercialization.

skyhawktx.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-04-22
Description

Ipsen entered an exclusive worldwide collaboration to discover and develop novel small molecules modulating RNA for rare neurological diseases. Deal worth up to $1.8 billion including upfront and milestone payments plus tiered royalties. Ipsen receives option to acquire exclusive global rights to two candidates following development candidate nomination, then assumes all further development and commercialization responsibilities. Ipsen brings neuroscience expertise in movement disorders.

3Bristol-Myers Squibb (BMS)
Strategic tierCoreTypeTechnology or Integration
Description

BMS collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas including neurodegenerative disease, autoimmune disease, and oncology. Upfront payments from pharma collaborations total over $550 million.

skyhawktx.com
Strategic tierCoreTypeTechnology or Integration
Description

Biogen collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Strategic tierCoreTypeTechnology or Integration
Description

Genentech collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Strategic tierCoreTypeTechnology or Integration
Description

Sanofi collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Strategic tierCoreTypeTechnology or Integration
Description

Takeda collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Strategic tierCoreTypeTechnology or Integration
Description

Vertex collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Strategic tierCoreTypeTechnology or Integration
Description

Merck & Co. collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PTC Therapeutics is the most direct comparable — a commercial-stage company that originated the RNA splicing modulator field with risdiplam (Evrysdi), co-invented by Skyhawk co-founder Sergey Paushkin. PTC operates the same small-molecule RNA splicing modality and shares Skyhawk's CNS/splicing therapeutic focus.

TypeDirect peer
Description

Wave is a leading direct competitor in Huntington's disease, developing allele-selective antisense oligonucleotides (WVE-003) targeting the same mHTT protein. Wave is the closest therapeutic rival to SKY-0515 in HD and shares the rare neurology/splicing-modulating therapeutic strategy.

TypeDirect peer
Description

uniQure is the principal gene therapy competitor in Huntington's disease with AMT-130 (AAV5-miHTT), currently pursuing accelerated approval. AMT-130 represents the primary modality-based competitive threat to SKY-0515 in the HD market.

TypeEmerging player
Description

Arrakis is a clinical-stage biotech developing direct RNA-targeting small molecules (rSM), operating a platform conceptually similar to Skyhawk's SKYSTAR. It represents the most direct emerging-platform competitor in RNA-binding small molecule discovery.

5Expansion Therapeutics
TypeEmerging player
Description

Expansion Therapeutics is developing small molecules that target repeat-expansion RNAs in diseases including Huntington's and myotonic dystrophy. It overlaps with Skyhawk on the rare neurology repeat-expansion biology (PMS1/CAG expansion) that SKY-0515 addresses.

TypeBroad incumbent
Description

Ionis is the established leader in antisense oligonucleotide (ASO) therapeutics with a broad neurology pipeline. Ionis developed tominersen (with Roche) for Huntington's disease and Spinraza for SMA, making it a direct therapeutic-area incumbent adjacent to Skyhawk's CNS focus.

TypeBroad incumbent
Description

Alnylam is the commercial leader in RNA interference (siRNA) therapeutics. While its modality differs from Skyhawk's small-molecule approach, Alnylam shares the RNA-targeting therapeutic category and competes for pharma partnership attention in RNA-targeted drug development.

TypeBroad incumbent
Description

BioMarin is a commercial-stage rare-disease biotech with CNS programs and proven specialty distribution economics. It is comparable as a model for how Skyhawk's HD and rare-neuro franchise could scale commercially once SKY-0515 launches.

TypeBroad incumbent
Description

Moderna is the leading commercial mRNA therapeutics company, providing a parallel RNA-modality comparable as Skyhawk scales its pipeline. While the therapeutic modality (mRNA versus RNA-binding small molecules) differs, both companies operate within the broader RNA therapeutics category.

TypeBroad incumbent
Description

Sage Therapeutics (now a Biogen subsidiary) developed CNS rare-disease therapies including Zurzuvae, with a comparable specialty neurology commercial profile. It is relevant as a peer for the commercial-stage rare neurology model Skyhawk is preparing to enter with SKY-0515.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Skyhawk Therapeutics

RNA-targeting small molecule therapeuticsskyhawktx.com

Skyhawk Therapeutics is a clinical-stage biotechnology company developing orally bioavailable small molecule RNA splicing modulators through its proprietary SKYSTAR platform to target historically undruggable proteins in neurodegenerative, oncology, and rare diseases, with lead asset SKY-0515 in Phase 2/3 for Huntington's disease.

What Skyhawk Therapeutics does

Skyhawk Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics that modulate RNA expression to address historically undruggable disease targets. The company's proprietary SKYSTAR platform integrates four complementary components — SKYSTAR (target assessment system combining bioinformatic, structural, and computational biology data), SKYLIBRARY (custom-built compound libraries), SKYSEQ (proprietary multiplex screening), and SKYAI (machine learning toolset) — to discover and advance orally bioavailable small molecules that act on RNA upstream of protein expression. The platform has been used to screen more than 700 RNA targets for pharma partners.

The company's lead asset, SKY-0515, is an oral small molecule RNA splicing modulator for Huntington's disease that targets two pathogenic mechanisms simultaneously — mutant huntingtin (mHTT) protein reduction and PMS1-mediated somatic CAG repeat expansion. SKY-0515 has progressed through Phase 1 trials (demonstrating up to 72% HTT mRNA reduction in healthy volunteers and 69% mHTT reduction at 12 months in patients) and is now enrolling a global Phase 2/3 FALCON-HD pivotal trial across 8 countries. Additional pipeline assets include SKY-1214 (an IND-ready FANCL/FANCI RNA splicing modulator for multiple myeloma and non-Hodgkin's lymphoma) and four preclinical rare neurological disease programs (SKY-0925, SKY-2100, SKY-4100, SKY-4200).

Skyhawk generates revenue through upfront payments, development and regulatory milestones, and tiered royalties from pharma collaborations, with over $550 million in upfront payments received to date from nine major partners including Bristol-Myers Squibb, Biogen, Genentech, Sanofi, Takeda, Vertex, Merck & Co., Merck KGaA (deal exceeding $2 billion), and Ipsen (deal worth up to $1.8 billion). The company has raised over $600 million in equity financing, including a $133 million round in September 2021 led by Fidelity. Headquartered in Waltham, Massachusetts with European operations in Basel, Switzerland, Skyhawk is preparing for direct commercial launch of SKY-0515 in Australia via the TGA provisional approval pathway (application submitted March 2026) and targeting major market approvals by 2027, supported by its appointment of a Chief Commercial Officer in March 2026.

Skyhawk Therapeutics firmographics

Firmographics
Name
Skyhawk Therapeutics
Legal name
Skyhawk Therapeutics, Inc.
Website
https://skyhawktx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Skyhawk Therapeutics is a clinical-stage biotechnology company developing orally bioavailable small molecule RNA splicing modulators through its proprietary SKYSTAR platform to target historically undruggable proteins in neurodegenerative, oncology, and rare diseases, with lead asset SKY-0515 in Phase 2/3 for Huntington's disease.
Ownership category
akta.pro rank

Skyhawk Therapeutics industry classification

Industry
Product category
RNA-targeting small molecule therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • RNA splicing modulators
  • Small molecule therapeutics
  • Neurology drug discovery
  • Targeted oncology therapeutics
  • Rare disease pipeline

Where Skyhawk Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Skyhawk Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Pharma Collaboration Payments and Milestones: Skyhawk generates revenue through upfront payments, milestone payments, and tiered royalties from pharma partnerships. Upfront payments from pharma collaborations total over $550 million, with additional potential from milestone payments under collaboration agreements including deals with Merck KGaA ($2B+ total deal value) and Ipsen (up to $1.8B total deal value).
  2. Pharmaceutical Product Sales (Future): Once regulatory approvals are obtained, Skyhawk plans to commercialize its proprietary pipeline products, starting with SKY-0515 for Huntington's disease, through direct commercial teams targeting healthcare providers and patients globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Skyhawk Therapeutics product offering

Product offering

Core offering

Skyhawk Therapeutics discovers and develops oral small molecule drug candidates that modify RNA expression to target historically undruggable proteins implicated in neurodegenerative, oncologic, neuromuscular, rare, and fibrotic diseases. Its clinical-stage pipeline is led by SKY-0515 for Huntington's disease (Phase 2/3 FALCON-HD pivotal trial) and includes SKY-1214 for multiple myeloma and non-Hodgkin's lymphoma (IND-ready), plus four preclinical rare neurology programs. The proprietary SKYSTAR discovery platform integrates SKYSTAR, SKYLIBRARY, SKYSEQ, and SKYAI to generate partnered and wholly-owned assets.

Product overview

Skyhawk Therapeutics is a clinical-stage biotechnology company developing a portfolio of small molecule RNA-modulating drug candidates. The core platform is SKYSTAR, which integrates four components (SKYSTAR target assessment, SKYLIBRARY compound libraries, SKYSEQ multiplex screening, and SKYAI machine learning) to discover RNA-targeting small molecules. Lead product SKY-0515 is in Phase 2/3 pivotal trial for Huntington's disease. Additional programs include SKY-1214 (IND-ready for oncology: multiple myeloma and NHL), SKY-0925, SKY-2100, SKY-4100, and SKY-4200 for rare neurological diseases. The company has collaborations with eight major pharmaceutical partners including BMS, Biogen, Genentech, Ipsen, Merck, Sanofi, Takeda, and Vertex. All drug candidates are small molecules taken orally with demonstrated blood-brain barrier penetration.

Differentiator

Problem solved

Functional benefit

Brands

  • SKYSTAR: Proprietary RNA-targeting small molecule drug discovery platform integrating bioinformatics, structural biology, and machine learning
  • SKYLIBRARY
  • SKYSEQ
  • SKYAI

Products and services

  • SKY-0515 Oral, once-daily small molecule RNA splicing modulator for early-stage Huntington's disease that simultaneously reduces mutant huntingtin (mHTT) protein and PMS1 mRNA. Currently in Phase 2/3 FALCON-HD pivotal trial with TGA provisional approval pathway eligibility in Australia and broader market entry anticipated by 2027.
  • SKY-1214 First-in-class oral FANCL/FANCI RNA splicing modulator for difficult-to-treat multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) that targets the Fanconi anemia DNA damage repair pathway. IND-ready with completed IND-enabling studies.
  • SKY-0925 Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options. Part of Skyhawk's internal neurology pipeline.
  • SKY-2100 Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options.
  • SKY-4100 Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options.
  • SKY-4200 Preclinical rare neurological disease program targeting an undisclosed indication with significant unmet need and limited therapeutic options.
  • SKYSTAR Platform Proprietary RNA-targeting small molecule drug discovery platform integrating target assessment (SKYSTAR), custom compound libraries (SKYLIBRARY), multiplex screening (SKYSEQ), and machine learning (SKYAI). Used to support partnered collaborations with Bristol-Myers Squibb, Biogen, Genentech, Sanofi, Takeda, Vertex, Merck (MSD), Ipsen, and Merck KGaA.

Quantifiable outcome

  • 69% reduction in mutant huntingtin protein (mHTT) at 9mg dose at 12 months in Phase 1/2 trial
  • +5 more outcomes

Companies that use Skyhawk Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Skyhawk Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Skyhawk Therapeutics partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major and core.

  • Merck KGaA, Darmstadt, GermanymajorStrategic or Co-development Partner · 18 August 2024Skyhawk entered an option agreement granting Merck KGaA exclusive global rights to drug candidates pursued under the collaboration upon option exercise. Total deal value exceeds $2 billion including upfront and milestone payments, along with royalties on future sales. Skyhawk uses its SKYSTAR platform to identify small molecule candidates directed at specific RNA targets designated by Merck KGaA in neurological indications. Following option exercise, Merck KGaA assumes responsibility for further development and commercialization.
  • IpsenmajorStrategic or Co-development Partner · 22 April 2024Ipsen entered an exclusive worldwide collaboration to discover and develop novel small molecules modulating RNA for rare neurological diseases. Deal worth up to $1.8 billion including upfront and milestone payments plus tiered royalties. Ipsen receives option to acquire exclusive global rights to two candidates following development candidate nomination, then assumes all further development and commercialization responsibilities. Ipsen brings neuroscience expertise in movement disorders.
  • Bristol-Myers Squibb (BMS)coreTechnology or IntegrationBMS collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas including neurodegenerative disease, autoimmune disease, and oncology. Upfront payments from pharma collaborations total over $550 million.
  • BiogencoreTechnology or IntegrationBiogen collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.
  • Genentech (Roche)coreTechnology or IntegrationGenentech collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.
  • SanoficoreTechnology or IntegrationSanofi collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.
  • TakedacoreTechnology or IntegrationTakeda collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.
  • VertexcoreTechnology or IntegrationVertex collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.
  • Merck & Co.coreTechnology or IntegrationMerck & Co. collaboration leverages Skyhawk's novel SKYSTAR platform to target challenging diseases across various therapeutic areas. Upfront payments from pharma collaborations total over $550 million.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Skyhawk Therapeutics competitors and assessment

Company assessment

Direct peers

  • PTC Therapeutics: PTC Therapeutics is the most direct comparable — a commercial-stage company that originated the RNA splicing modulator field with risdiplam (Evrysdi), co-invented by Skyhawk co-founder Sergey Paushkin. PTC operates the same small-molecule RNA splicing modality and shares Skyhawk's CNS/splicing therapeutic focus.
  • Wave Life Sciences: Wave is a leading direct competitor in Huntington's disease, developing allele-selective antisense oligonucleotides (WVE-003) targeting the same mHTT protein. Wave is the closest therapeutic rival to SKY-0515 in HD and shares the rare neurology/splicing-modulating therapeutic strategy.
  • uniQure: uniQure is the principal gene therapy competitor in Huntington's disease with AMT-130 (AAV5-miHTT), currently pursuing accelerated approval. AMT-130 represents the primary modality-based competitive threat to SKY-0515 in the HD market.

Emerging players

  • Arrakis Therapeutics: Arrakis is a clinical-stage biotech developing direct RNA-targeting small molecules (rSM), operating a platform conceptually similar to Skyhawk's SKYSTAR. It represents the most direct emerging-platform competitor in RNA-binding small molecule discovery.
  • Expansion Therapeutics: Expansion Therapeutics is developing small molecules that target repeat-expansion RNAs in diseases including Huntington's and myotonic dystrophy. It overlaps with Skyhawk on the rare neurology repeat-expansion biology (PMS1/CAG expansion) that SKY-0515 addresses.

Broad incumbents

  • Ionis Pharmaceuticals: Ionis is the established leader in antisense oligonucleotide (ASO) therapeutics with a broad neurology pipeline. Ionis developed tominersen (with Roche) for Huntington's disease and Spinraza for SMA, making it a direct therapeutic-area incumbent adjacent to Skyhawk's CNS focus.
  • Alnylam Pharmaceuticals: Alnylam is the commercial leader in RNA interference (siRNA) therapeutics. While its modality differs from Skyhawk's small-molecule approach, Alnylam shares the RNA-targeting therapeutic category and competes for pharma partnership attention in RNA-targeted drug development.
  • BioMarin Pharmaceutical: BioMarin is a commercial-stage rare-disease biotech with CNS programs and proven specialty distribution economics. It is comparable as a model for how Skyhawk's HD and rare-neuro franchise could scale commercially once SKY-0515 launches.
  • Moderna: Moderna is the leading commercial mRNA therapeutics company, providing a parallel RNA-modality comparable as Skyhawk scales its pipeline. While the therapeutic modality (mRNA versus RNA-binding small molecules) differs, both companies operate within the broader RNA therapeutics category.
  • Sage Therapeutics (acquired by Biogen): Sage Therapeutics (now a Biogen subsidiary) developed CNS rare-disease therapies including Zurzuvae, with a comparable specialty neurology commercial profile. It is relevant as a peer for the commercial-stage rare neurology model Skyhawk is preparing to enter with SKY-0515.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Skyhawk Therapeutics social profiles

Digital presence

Skyhawk Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Skyhawk Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Skyhawk Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Skyhawk Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Skyhawk Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skyhawk Therapeutics

What does Skyhawk Therapeutics do?

Skyhawk Therapeutics discovers and develops oral small molecule drug candidates that modify RNA expression to target historically undruggable proteins implicated in neurodegenerative, oncologic, neuromuscular, rare, and fibrotic diseases. Its clinical-stage pipeline is led by SKY-0515 for Huntington's disease (Phase 2/3 FALCON-HD pivotal trial) and includes SKY-1214 for multiple myeloma and non-Hodgkin's lymphoma (IND-ready), plus four preclinical rare neurology programs. The proprietary SKYSTAR discovery platform integrates SKYSTAR, SKYLIBRARY, SKYSEQ, and SKYAI to generate partnered and wholly-owned assets.

Is Skyhawk Therapeutics a public or private company?

Skyhawk Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Skyhawk Therapeutics founded?

Skyhawk Therapeutics was founded in 2018. It employs 51 to 100 people.

Where is Skyhawk Therapeutics based?

Skyhawk Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Skyhawk Therapeutics make money?

Two revenue lines are on record. Pharma Collaboration Payments and Milestones are the primary driver. The others are pharmaceutical Product Sales (Future).

Who are Skyhawk Therapeutics's main competitors?

Direct peers on record are PTC Therapeutics, Wave Life Sciences and uniQure. Emerging players are Arrakis Therapeutics and Expansion Therapeutics. Broad incumbents are Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Moderna and Sage Therapeutics (acquired by Biogen).

Does Skyhawk Therapeutics have an API?

No public API is recorded for Skyhawk Therapeutics.

What industry is Skyhawk Therapeutics in?

Skyhawk Therapeutics's product category is RNA-targeting small molecule therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSkyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's DiseaseSkyhawk Therapeutics announced the first U.S. patients have been dosed in the pivotal FALCON-HD study for SKY-0515 in Huntington's disease, with dosing starting at a Colorado center. Over 50,000 doses have been administered across 30+ sites in 10 countries. Additional U.S. sites, including Beth Israel Deaconess, are expected to begin dosing in coming weeks.PR NewswireSkyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's DiseaseSkyhawk Therapeutics announced the first U.S. patients have been dosed in the pivotal FALCON-HD study for SKY-0515 in Huntington's disease, with dosing starting at a Colorado center. Over 50,000 doses have been administered across 30+ sites in 10 countries. Additional U.S. sites, including Beth Israel Deaconess, are expected to begin dosing in coming weeks.GlobeNewswireRNA Targeting Small Molecule Drug Discovery Market - Global Forecast, 2021-2031F | 22.13% CAGR to Propel Market to USD 6.47 Billion as Pharma Partnerships AccelerateThe global RNA-targeting small molecule drug discovery market is projected to grow from $1.95 billion in 2025 to $6.47 billion by 2031, a 22.13% CAGR. Growth is driven by partnerships like Wayfinder Biosciences and Daiichi Sankyo, and clinical progress such as Skyhawk Therapeutics' positive Phase 1 results.BioPharma DiveSkyhawk racks up more support for Huntington’s drugSkyhawk Therapeutics announced final results from a small study of its Huntington's drug, showing patients improved by an average of 0.94 points on a functional scale after 15 months. The improvement was 1.59 points better than untreated patients, and the drug lowered mutant huntingtin protein by over 60%. The company is now evaluating the drug in two larger clinical trials.Endpoints NewsSkyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trialSkyhawk Therapeutics reported that its RNA-splicing candidate for Huntington's disease improved patients' symptoms in an extension to a Phase 1/2 trial. The company said the therapy showed symptom improvement and is moving to pivotal development.BioSpaceSkyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease PatientsSkyhawk Therapeutics announced final 15-month results from its Phase 1/2 trial of SKY-0515 in Huntington's disease patients. At Month 15, treated patients improved by 0.94 points on cUHDRS versus a decline of 0.65 points in the external control, a 1.59-point difference (p<0.001). The drug reduced mutant huntingtin protein by over 60% and PMS1 mRNA by over 25% at the 9 mg dose.Neurology liveSkyhawk’s SKY-0515 Shows Significant Lowering of Huntingtin mRNA in Phase 1 StudySkyhawk Therapeutics reported Phase 1 trial data showing SKY-0515 reduced mutant huntingtin mRNA by an average of 72% in healthy volunteers at a 9 mg daily dose. Recruitment for Part C, which includes Huntington disease patients, has begun, with topline data expected in Q2 2025.Neurology liveSKY-0515 Demonstrates Dose-Dependent Reductions in Mutant Huntingtin Protein in Phase 1 UpdateSkyhawk Therapeutics reported phase 1 update data showing SKY-0515 reduced mutant huntingtin protein by 62% at the 9-mg dose and 29% at 3 mg in early-stage Huntington disease patients. The treatment was well tolerated, and topline data from the blinded extension are expected in mid-2026.Neurology livePatient Dosing Underway in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington DiseaseSkyhawk Therapeutics announced the first patient was dosed in its phase 2/3 FALCON-HD trial of SKY-0515, an oral RNA splicing modulator for Huntington disease. The trial enrolls about 120 participants across 10 sites, with phase 1 data showing a 72% reduction in HTT mRNA at the highest dose. The company hopes the dual-target mechanism may offer advantages over prior therapies.Clinical LeaderThe Patient Advocacy Strategy Behind Skyhawk's Rapid EnrollmentSkyhawk Therapeutics' executives discuss how direct patient advocacy and in-person engagement drove rapid enrollment in SKY-0515 trials for Huntington's disease. The Phase 2/3 trial enrolled 144 patients by April 2026, exceeding its 120-patient goal by 20% and finishing four to five months early. The company plans to open sites in Latin America and the U.S.